¶ Emergent BioSolutions
.png)
This page has moved! Click here to view the most up-to-date version of this page on the White Rose Wiki.
Emergent BioSolutions, formerly BioPort, is an American biopharmaceutical company based in Gaithersburg, Maryland.
¶ History
Emergent BioSolutions was founded on September 5, 1998 by Fuad El-Hibri under the name BioPort, for the sole purpose of acquiring the newly-privatized Michigan Biologic Products Institute (MBPI).[1][2]
In December 2003, the company underwent a corporate restructure and continued operations under the name Emergent BioSolutions beginning in June 2004.[3] Jerome Hauer, former acting assistant secretary of the Office of Public Health Emergency Preparedness at the United States Department of Health and Human Services, joined the company's board of directors in May 2004.[4]
On July 14, 2017, Emergent BioSolutions announced it had struck a deal with Sanofi to acquire ACAM2000, the only smallpox vaccine approved by the Food and Drug Administration at the time.[5]
On October 16, 2018, the Coalition for Epidemic Preparedness Innovations (CEPI) announced a $36 million grant to Emergent and Profectus BioSciences to develop and manufacture a vaccine against Lassa virus, in collaboration with the Program for Appropriate Technologies in Health (PATH).[6][7]
Several representatives from Emergent attended BARDA Industry Day 2018 from October 29-30 in Washington, D.C.[8]
¶ COVID-19
On April 23, 2020, Emergent BioSolutions announced it had entered a $135 million agreement with Johnson & Johnson to "provide contract development and manufacturing services" for the Janssen COVID-19 vaccine.[9]
In June 2020, AstraZeneca and Emergent partnered to manufacture their COVID-19 vaccine product.[10][11]
On July 6, 2020, Emergent BioSolutions announced an additional five-year contract with Johnson & Johnson, building on the prior agreement.[12] After the first two years, Emergent would "provide a flexible capacity deployment model to support additional drug substance batches annually."[13]
Some 10-15 million doses of the AstraZeneca COVID-19 vaccine were discarded at Emergent's plant in Baltimore, Maryland due to suspected contamination. This was followed in March 2021 when Emergeent discarded up to 15 million doses of Janssen and AstraZeneca's COVID-19 vaccines after mixing up ingredients between the two. The mistake was attributed to "human error."[14]
In April 2021, the Food and Drug Administration (FDA) requested that Emergent "suspend manufacture of new drug substance and quarantine existing material manufactured" at the plant.[15]
Emergent sponsored the World Vaccine Congress Washington 2022 from April 18-21 in Washington, D.C.[16]
¶ Organization
Emergent BioSolutions is a member of:
- Ad Standards[17]
- Advanced Medical Technology Association (AdvaMed)[18]
- Alliance for Biosecurity[19]
- Biotechnology Innovation Organization (BIO)[20]
- Consumer Healthcare Products Association (CHPA)[21]
- GBCHealth[22]
- Global Health Security Agenda Consortium[23]
- Innovative Medicines Canada[24]
- Medical CBRN Defense Consortium[25]
- Pandemic Action Network[26]
Emergent has provided notable funding to:
- Aeras Global TB Vaccine Foundation[27]
- Bipartisan Commission on Biodefense[28]
- CDC Foundation[29]
- Community Anti-Drug Coalitions of America (CADCA)[30]
- Diabetes Canada[31]
- SickKids Foundation[32]
Additionally, Stanley Plotkin reported in 2015 that he had received "personal fees" from Emergent BioSolutions.[33]
Emergent is a client of the Pharmaceutical Advertising Advisory Board (PAAB).[34]
¶ Personnel
| Name | Position | Notes |
|---|---|---|
| Emma Wheatley | VP Legal Affairs and Deputy General Counsel (former)[35] | Coalition for Epidemic Preparedness Innovations (CEPI)[36] |
¶ External links
Webb, W. (2020, April 9). A Killer Enterprise: How One of Big Pharma’s Most Corrupt Companies Plans to Corner the Covid-19 Cure Market. The Last American Vagabond. http://archive.today/2020.08.03-071008/https://www.thelastamericanvagabond.com/killer-enterprise-how-big-pharmas-most-corrupt-companies-plans-corner-covid-19-cure-market/ ↩︎
What about Bioport? (2002, January 11). Mackinac Center. https://web.archive.org/web/20230721234706/https://www.mackinac.org/3966 ↩︎
$100,000,000 of Common Stock Preferred Stock Debt Securities Warrants. (2008, December 10). Emergent BioSolutions. https://web.archive.org/web/20230722163134/https://investors.emergentbiosolutions.com/static-files/6bc4d32b-9037-47fc-8f1c-0f58f2c85912 ↩︎
Jerome M. Hauer Ph.D, M.H.S. Emergent BioSolutions. Retrieved April 23, 2020, from http://archive.today/2020.04.23-084601/https://investors.emergentbiosolutions.com/board-member/jerome-hauer ↩︎
Liu, A. (2017, July 18). Sanofi offloads smallpox vaccine business to Emergent BioSolutions in $125M deal. Fierce Pharma. https://web.archive.org/web/20170718181654/https://www.fiercepharma.com/vaccines/emergent-biosolutions-buys-sanofi-s-smallpox-vaccine-for-125m ↩︎
Grant, R., Christodoulou, M., Moynihan, M., Burrows, R. G., & Kieffer, L. (2018, August 16). CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine. Emergent BioSolutions. https://web.archive.org/web/20230722185423/https://www.emergentbiosolutions.com/press/news-release-details-cepi-awards-contract-worth-36-million-profectus-biosciences-and/ ↩︎
Our portfolio. CEPI. Retrieved October 21, 2022, from https://web.archive.org/web/20221021070613/https://cepi.net/research_dev/our-portfolio/ ↩︎
Participant List. BARDA. Retrieved February 27, 2023, from https://web.archive.org/web/20230227080444/https://www.medicalcountermeasures.gov/BARDA/documents/BID2018_ParticipantList.pdf ↩︎
Neri, M. B., & Burrows, R. G. (2020, April 23). Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19. Emergent BioSolutions. https://archive.ph/2023.06.14-015555/https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing?field_nir_news_date_value[min]= ↩︎
Blankenship, K. (2020, June 11). AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine. FiercePharma. http://archive.today/2022.05.12-232222/https://www.fiercepharma.com/manufacturing/astrazeneca-emergent-biosolutions-sign-87m-deal-to-produce-u-s-supply-covid-vaccine ↩︎
Neri, M. B. (2020, June 11). Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate. Emergent BioSolutions. http://archive.today/2022.05.12-231724/https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing-0?field_nir_news_date_value[min]= ↩︎
Knapp, A. (2021, March 1). Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine. Forbes. http://archive.today/2022.05.12-231258/https://www.forbes.com/sites/alexknapp/2021/03/01/little-known-publicly-traded-company-given-massive-deal-to-manufacture-one-shot-covid-19-vaccine/?sh=95c20f232171 ↩︎
Neri, M. B., & Burrows, R. G. (2020, July 6). Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate. Emergent BioSolutions. http://archive.today/2023.06.14-014540/https://www.emergentbiosolutions.com/press/news-release-details-emergent-biosolutions-signs-five-year-agreement-large-scale-drug/ ↩︎
LaFraniere, S., & Weiland, N. (2021, March 31). Factory Mix-Up Ruins Up to 15 Million Vaccine Doses From Johnson & Johnson. The New York Times. https://web.archive.org/web/20210418220356/https://www.nytimes.com/2021/03/31/us/politics/johnson-johnson-coronavirus-vaccine.html ↩︎
Dunleavy, K. (2021, April 19). FDA orders shutdown at Emergent’s troubled plant 2 weeks after handing J&J the keys. Fierce Pharma. https://web.archive.org/web/20210419145104/https://www.fiercepharma.com/pharma/at-request-fda-emergent-s-troubled-baltimore-plant-suspends-j-j-vaccine-production ↩︎
Sponsors & exhibitors | Vaccine Congress USA. (2022, April 21). World Vaccine Congress Washington 2022. http://archive.today/2022.04.22-012231/https://www.terrapinn.com/conference/world-vaccine-congress-washington/sponsors-and-exhibitors.stm ↩︎
Member Logos. Ad Standards. Retrieved September 17, 2021, from https://web.archive.org/web/20210917052119/https://adstandards.ca/about/membership/member-logos/ ↩︎
Members. AdvaMed. Retrieved July 13, 2014, from http://archive.today/2014.07.13-182356/http://advamed.org/page/33/members ↩︎
Who we are. Alliance for Biosecurity. Retrieved June 20, 2022, from http://archive.today/2022.05.22-144645/https://www.allianceforbiosecurity.com/who-we-are ↩︎
BIO Member Directory. Biotechnology Innovation Organization. Retrieved September 30, 2022, from https://web.archive.org/web/20220930103715/https://www.bio.org/bio-member-directory ↩︎
Member Companies. Consumer Healthcare Products Association. Retrieved October 5, 2022, from https://web.archive.org/web/20221005193943/https://my.chpa.org/Directories/Member-Companies ↩︎
GBCHealth Member Directory. (2013). GBCHealth. http://archive.today/2023.01.11-041556/https://archive.gbchealth.org/our-coalition/member-directory/ ↩︎
Member Profile Archives. Global Health Security Agenda Consortium (GHSAC). Retrieved August 16, 2022, from https://web.archive.org/web/20220816152920/https://ghsacngs.org/pl-categs/member-profile/ ↩︎
About. Innovative Medicines Canada. Retrieved July 16, 2023, from https://web.archive.org/web/20230716180353/https://innovativemedicines.ca/web/20230716180353/https://innovativemedicines.ca/about/#member-companies ↩︎
Current Members. MCDC. Retrieved January 3, 2023, from http://archive.today/2023.01.03-195328/https://www.medcbrn.org/current-members/ ↩︎
Our Network. Pandemic Action Network. Retrieved July 23, 2022, from https://web.archive.org/web/20220724022128/https://www.pandemicactionnetwork.org/our-network/ ↩︎
Funders and Partners. Aeras. Retrieved July 24, 2018, from http://archive.today/2018.07.24-024017/http://www.aeras.org/pages/funders ↩︎
Sponsors / Donors. Bipartisan Commission on Biodefense. Retrieved May 28, 2022, from http://archive.today/2022.05.29-040043/https://biodefensecommission.org/sponsors-donors/ ↩︎
FY2016 - Corporations, Foundations and Organizations. CDC Foundation. Retrieved August 9, 2022, from https://web.archive.org/web/20220809055009/https://www.cdcfoundation.org/FY2016/organizations ↩︎
Price, B. L. (2020). Annual Report 2020. Community Anti-Drug Coalitions of America. https://web.archive.org/web/20210909044152/http://www.cadcaannualreport.org/2020/CADCA-2020-AnnualReport.pdf ↩︎
2020 Impact Report. (2020). Diabetes Canada. https://web.archive.org/web/20220121173802/https://diabetes.ca/DiabetesCanadaWebsite/media/AboutDiabetesCanada/Finance/DC-2020-Impact-Report-DIGITAL.pdf ↩︎
2020-21 SickKids Annual Report. SickKids Foundation. Retrieved January 20, 2022, from http://archive.today/2022.01.20-213118/https://web.sickkidsfoundation.com/annual-report-2020/ ↩︎
Plotkin, S. (2015). ICMJE Form for Disclosure of Potential Conflicts of Interest (p. 8). New England Journal of Medicine. https://web.archive.org/web/20221020003030/https://www.nejm.org/doi/suppl/10.1056/NEJMp1506820/suppl_file/nejmp1506820_disclosures.pdf ↩︎
About. Pharmaceutical Advertising Advisory Board / Conseil Consultatif de Publicité Pharmaceutique. Retrieved August 28, 2022, from https://web.archive.org/web/20220828145658/https://www.paab.ca/about.htm ↩︎
Emma Wheatley. LinkedIn. Retrieved July 22, 2023, from https://www.linkedin.com/in/emmawheatley28/ ↩︎
Who we are. CEPI. Retrieved October 19, 2022, from https://web.archive.org/web/20221019165747/https://cepi.net/about/whoweare/ ↩︎